IDEXX LaboratoriesFRA:IX1 +2.86%96 PS Ratio is 9.94 as of Jul. 03, 2026, which is 5% below its 10-year median of 10.41. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €534.01 (Modestly Undervalued). Among 200 Medical Diagnostics & Research companies, IDEXX Laboratories ranks worse than 82.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, IDEXX Laboratories's share price is €471.40.
IDEXX Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €47.43. Hence, IDEXX Laboratories's PS Ratio for today is 9.94.
Good Sign:
IDEXX Laboratories Inc stock PS Ratio (=10.11) is close to 1-year low of 9.58.
The historical rank and industry rank for IDEXX Laboratories's PS Ratio or its related term are showing as below:
FRA:IX1'
s PS Ratio Range Over the Past 10 Years
Min: 5.06 Med: 10.41 Max: 19.77
Current: 10.11
During the past 13 years, IDEXX Laboratories's highest PS Ratio was 19.77. The lowest was 5.06. And the median was 10.41.
FRA:IX1's PS Ratio is ranked worse than 82.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.825
vs FRA:IX1: 10.11
IDEXX Laboratories Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of IDEXX Laboratories was 16.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 12.00% per year.
During the past 13 years, IDEXX Laboratories's highest 3-Year average Revenue per Share Growth Rate was 35.60% per year. The lowest was 8.00% per year. And the median was 13.25% per year.
Back to Basics: PS Ratio
IDEXX Laboratories (FRA:IX1) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
IDEXX Laboratories PS Ratio Related Terms
IDEXX Laboratories PS Ratio Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
IDEXX Laboratories's Share Price of today is €471.40. IDEXX Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €47.43.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
IDEXX Laboratories (FRA:IX1) has a PS Ratio of 9.94 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IDEXX Laboratories and its competitors. This is near median its historical median of 10.41. Over the past decade, IDEXX Laboratories' PS Ratio has ranged from 5.06 to 19.77. According to the industry distribution chart, IDEXX Laboratories ranks #165 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 82.5%.
Is IDEXX Laboratories' PS Ratio too high?
IDEXX Laboratories' current PS Ratio of 9.94 is near median its 10-year median of 10.41. Over the past 10 years, this metric has ranged from a low of 5.06 to a high of 19.77. The Medical Diagnostics & Research industry median PS Ratio is 2.83. IDEXX Laboratories' value of 9.94 is 251.9% above this industry median. Based on the distribution chart, IDEXX Laboratories ranks #165 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' PS Ratio compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #165 out of 200 companies for PS Ratio. This places IDEXX Laboratories in the lower half of its industry. The industry median PS Ratio is 2.83. IDEXX Laboratories' value of 9.94 is 251.9% above this benchmark. Historically, IDEXX Laboratories' own PS Ratio has ranged from 5.06 to 19.77 over the past decade. While the company's 10-year median is 10.41 vs. the industry median of 2.83, IDEXX Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.83, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDEXX Laboratories's current PS Ratio of 9.94 is 251.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current PS Ratio is 9.94, which is near median its own 10-year median of 10.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €534.01, compared to a current price of €471.40 — trading 11.7% below its estimated fair value. The current PS Ratio is 9.94, which is near median its 10-year median of 10.41 and 251.9% above the Medical Diagnostics & Research industry median of 2.83. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current PS Ratio is 9.94 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €471.40 is trading 11.7% below its estimated GF Value™ of €534.01.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
PS Ratio: 9.94 (near median its 10-year median of 10.41)
GF Value™: €534.01 vs. price of €471.40 (11.7% below fair value)
Industry Position: 251.9% above the Medical Diagnostics & Research median (#165 of 200)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
